DCSIMG
Anxiety & Insomnia
Sanofi Logo
Text Size – + |   FAQs  |  Site Map  |  Contact Us  |   Consumer Site
For U.S. Healthcare Professionals Only
AMBIEN CR (Zolpidem Tartrate Extended Release) Sleep Aid

FOR HEALTHCARE PROFESSIONALS

Give your patients
a good night's sleep...
FOR LESS

Share the AMBIEN CR Offer Card with your patients for up to $20* off each of their next 12 prescriptions.

Learn More
Skip Navigation Links

Insomnia & Anxiety

Email to Your Friend Send to a Friend   Print Print Page

44% of patients with Generalized Anxiety Disorder (GAD) also suffer from insomnia.16 When treating insomnia and co-morbid GAD with only an SSRI, the insomnia may not be sufficiently addressed.17,19,22,23

Help Patients Get Better Sleep with AMBIEN CR 2

In a clinical trial, patients with insomnia and co-morbid GAD were treated with AMBIEN CR plus an SSRI throughout 8 weeks.17

Results show17:

  • The AMBIEN CR/SSRI treatment group showed significantly more improvement in total sleep time (TST) than did patients treated with placebo and an SSRI.
  • Patients taking AMBIEN CR and an SSRI showed improvement as early as Week 1 in sleep onset latency, number of awakenings, and wake time after sleep onset compared with placebo and an SSRI.
  • These improvements were sustained during the 8 weeks of treatment.
SUMMARY OF INCREASED MEAN TST IN MINUTES,BY TREATMENT GROUP AND VISIT

N=381

*P<0.0001.

† In a randomized, double-blind, parallel-group, placebo-controlled,
8-week, phase IV trial of AMBIEN CR 12.5 mg, 381 adults with insomnia associated with GAD were treated concomitantly with the SSRI Lexapro® vs placebo and the SSRI Lexapro. The primary efficacy variable was change in TST from baseline to Week 8.

§ Lexapro (escitalopram oxalate) is a registered trademark of Forest Pharmaceuticals, Inc.

Improved Sleep-Related Next-Day Function.

In addition to improved sleep, patients with co-morbid GAD and insomnia who took AMBIEN CR plus an SSRI showed improved sleep-related next-day function, including more morning energy and concentration.17

As measured by the Sleep Impact Scalea questionnaire, patients taking AMBIEN CR demonstrated significant improvement in the following 4 domains (beyond that of patients taking an SSRI/placebo)17:

Next: Insomnia Patient Discussion Guide

pagedivide

* Maximum benefit is $240 off, up to $20 off each prescription (up to 12 prescriptions), depending on your out-of-pocket costs. Not valid for patients participating in Medicare, Medicaid, government (public insurance) programs, or any private payor in the state of Massachusetts and where prohibited by law.

AMBIEN CR is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. AMBIEN CR is not indicated for the treatment of GAD or MDD.

Due to its rapid onset of action, patients should take AMBIEN CR right before going to bed and when ready for sleep.

IMPORTANT SAFETY INFORMATION

Patients should not take AMBIEN CR unless they are prepared to get a full night’s sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect their physical or mental performance upon awakening, patients should not drive or operate hazardous machinery after taking AMBIEN CR or any other sleep medication. Complex behaviors such as somnambulism, including driving or eating while not fully awake, with amnesia for the event, as well as abnormal behaviors such as being more outgoing or aggressive than normal, confusion, agitation, and hallucinations may occur. AMBIEN CR should not be taken with alcohol as it may increase these abnormal behaviors. Discontinuation of AMBIEN CR should be strongly considered for patients reporting such complex behaviors. Angioedema may occur in patients taking AMBIEN CR and in rare cases may be fatal. Patients who develop angioedema should not be rechallenged. In primarily depressed patients, worsening of depression, including risk of suicidal thoughts or actions, including completed suicides, have been reported. Therefore, AMBIEN CR should be administered with caution to patients exhibiting signs or symptoms of depression, in whom suicidal tendencies may be present and protective measures may be required. Intentional overdosage is more common in this group of patients; the least amount of drug that is feasible should be prescribed for the patient at any one time.The most commonly observed adverse events in controlled clinical trials were headache, somnolence, and dizziness.

Please refer to the full prescribing information.